HB399

Montana HB399 revises prior authorization laws to prohibit certain types of prior authorizations for specific prescription drugs.

Montana HB399 amends prior authorization laws to prohibit prior authorization for oral and inhaled generic prescription drugs, inhaled prescription drugs for asthma, chronic obstructive pulmonary disease, or chronic lung disease, and insulin. It also mandates that any adverse determination for a prescription drug during prior authorization must be made by a physician specializing in the condition being treated. If an insurer makes an adverse determination, it must provide a written notice including a list of reasonable therapeutic alternatives covered by the insurer's formulary.